Core Viewpoint - The Schall Law Firm is investigating Alto Neuroscience, Inc. for potential violations of securities laws following the announcement that its Phase 2b study of ALTO-100 for major depressive disorder did not meet its primary endpoint, leading to a significant drop in the company's stock price [1]. Group 1 - The investigation by the Schall Law Firm focuses on whether Alto Neuroscience made false or misleading statements or failed to disclose important information to investors [1]. - On October 22, 2024, Alto Neuroscience reported that the Phase 2b study of ALTO-100 did not meet its primary endpoint, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [1]. - Following this announcement, shares of Alto Neuroscience fell by nearly 60% in after-hours trading on the same day [1].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-Q _________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-41944 _________________________ | --- | --- | |---------- ...

Exhibit 99.1 1 Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights – Completed enrollment of 301 patients in Phase 2b MDD study for ALTO-100; Investor Day focused on ALTO-100 planned for September 9, 2024; topline data expected in October 2024 – – Initiated multiple Phase 2 studies: ALTO-101 in schizophrenia, ALTO-203 in MDD with anhedonia, and ALTO-100 in bipolar depression – – Reported positive Phase 1 data on transdermal formulation of our novel PDE4 inhibitor, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-41944 _________________________ Alto Neuroscience, Inc. (Exact name of registrant ...

Exhibit 99.1 Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights – Initiated Phase 2 study of ALTO-203 in patients with MDD and anhedonia-– – Reported positive Phase 1 data with transdermal formulation of novel PDE4 inhibitor, ALTO-101; achieved significantly greater drug exposure with improved tolerability compared to oral administration – – Patient enrollment on track across Phase 2b MDD studies for ALTO-100 and ALTO-300 – – Strong cash position of approximately $ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ___________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-41944 _____________________________________________________ Alto Neur ...

Exhibit 99.1 Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights – Reported positive results from ALTO-100 and ALTO-300 Phase 2a studies demonstrating prospective replication of response prediction using Alto's Precision Psychiatry Platform™ – – Patient enrollment on track across Phase 2b MDD studies for two lead product candidates – – Successful completion of oversubscribed initial public offering; cash position of approximately $210 million as of February 29, 2024 – L ...